Y Intercept Hong Kong Ltd Takes Position in Vaxcyte, Inc. $PCVX

Y Intercept Hong Kong Ltd acquired a new position in shares of Vaxcyte, Inc. (NASDAQ:PCVX) during the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund acquired 73,283 shares of the company’s stock, valued at approximately $2,640,000. Y Intercept Hong Kong Ltd owned approximately 0.06% of Vaxcyte at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also modified their holdings of PCVX. Universal Beteiligungs und Servicegesellschaft mbH raised its holdings in Vaxcyte by 32.6% during the third quarter. Universal Beteiligungs und Servicegesellschaft mbH now owns 34,150 shares of the company’s stock worth $1,230,000 after purchasing an additional 8,392 shares during the last quarter. J.Safra Asset Management Corp increased its position in shares of Vaxcyte by 47.0% in the third quarter. J.Safra Asset Management Corp now owns 5,984 shares of the company’s stock valued at $216,000 after buying an additional 1,912 shares in the last quarter. Sumitomo Mitsui Trust Group Inc. acquired a new position in shares of Vaxcyte during the 3rd quarter worth $301,000. Nisa Investment Advisors LLC boosted its position in shares of Vaxcyte by 96.3% in the 3rd quarter. Nisa Investment Advisors LLC now owns 3,254 shares of the company’s stock worth $117,000 after buying an additional 1,596 shares in the last quarter. Finally, SG Americas Securities LLC grew its stake in Vaxcyte by 129.5% in the 3rd quarter. SG Americas Securities LLC now owns 25,558 shares of the company’s stock valued at $921,000 after acquiring an additional 14,421 shares during the last quarter. Institutional investors and hedge funds own 96.78% of the company’s stock.

Analyst Ratings Changes

A number of brokerages have issued reports on PCVX. BTIG Research restated a “buy” rating and set a $85.00 target price on shares of Vaxcyte in a research report on Monday, November 10th. Needham & Company LLC lifted their price objective on Vaxcyte from $90.00 to $110.00 and gave the stock a “buy” rating in a research report on Wednesday, January 7th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Vaxcyte in a research note on Friday, January 9th. Finally, Leerink Partners set a $77.00 price target on Vaxcyte and gave the stock an “outperform” rating in a research report on Wednesday, November 19th. One analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, Vaxcyte presently has a consensus rating of “Moderate Buy” and an average price target of $101.17.

Vaxcyte Stock Down 1.4%

PCVX stock opened at $52.68 on Wednesday. The stock has a market capitalization of $6.90 billion, a price-to-earnings ratio of -10.88 and a beta of 1.34. Vaxcyte, Inc. has a 52-week low of $27.66 and a 52-week high of $93.77. The stock’s fifty day simple moving average is $47.17 and its 200-day simple moving average is $40.51.

Vaxcyte (NASDAQ:PCVX) last issued its earnings results on Tuesday, November 4th. The company reported ($1.56) earnings per share for the quarter, missing the consensus estimate of ($1.27) by ($0.29). During the same period in the prior year, the business earned ($0.83) earnings per share. As a group, analysts anticipate that Vaxcyte, Inc. will post -4.21 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Vaxcyte news, insider Harpreet S. Dhaliwal sold 9,743 shares of the stock in a transaction on Wednesday, December 31st. The shares were sold at an average price of $46.69, for a total transaction of $454,900.67. Following the transaction, the insider directly owned 23,928 shares of the company’s stock, valued at $1,117,198.32. This represents a 28.94% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, SVP Elvia Cowan sold 11,623 shares of the business’s stock in a transaction dated Tuesday, December 23rd. The stock was sold at an average price of $47.92, for a total value of $556,974.16. Following the completion of the sale, the senior vice president directly owned 14,534 shares of the company’s stock, valued at $696,469.28. This represents a 44.44% decrease in their position. The disclosure for this sale is available in the SEC filing. 3.10% of the stock is owned by insiders.

Vaxcyte Profile

Vaxcyte, Inc (NASDAQ: PCVX) is a clinical-stage biotechnology company focused on developing a new generation of preventive vaccines aimed at combating serious bacterial diseases. Headquartered in San Carlos, California, Vaxcyte leverages proprietary conjugation technologies to design and manufacture multivalent vaccines targeting pathogens for which there remain significant unmet medical needs. The company’s platform is intended to streamline the production of conjugate vaccines by improving antigen presentation and broadening strain coverage compared with conventional approaches.

Vaxcyte’s lead candidate, VAX-24, is a 24-valent pneumococcal conjugate vaccine designed to protect against 24 serotypes of Streptococcus pneumoniae.